Skip to main content
SpringerLink
Log in

Patient-Derived Bladder Cancer Xenografts

  • Protocol
  • First Online:
Urothelial Carcinoma

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1655))

Abstract

Patient-derived xenograft (PDX ) tumors are models developed by direct transplant of human tumors into immune-compromised hosts such as nude mice. These models retain the histological and genetic characteristics of the primary tumor and are considered a valuable platform for translational cancer research. This chapter describes the methodology to establish and propagate bladder cancer PDX model.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Hidalgo M, Amant F, Biankin AV et al (2014) Patient-derived Xenograft models: an emerging platform for translational cancer research. Cancer Discov 4:998–1013. doi:10.1158/2159-8290.CD-14-0001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Tentler JJ, Tan AC, Weekes CD et al (2012) Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9:338–350. doi:10.1038/nrclinonc.2012.61

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Voskoglou-nomikos T, Pater JL, Seymour L (2003) Clinical predictive value of the in vitro cell line, human Xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9:4227–4239

    PubMed  Google Scholar 

  4. Cobb LM (1973) The behaviour of carcinoma of the large bowel in man following transplantation into immune deprived mice. Br J Cancer 28:400–411

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Houghton JA, Houghton PJ, Green AA (1982) Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice. Cancer Res 42:535–539

    CAS  PubMed  Google Scholar 

  6. Fiebig HH, Schuchhardt C, Henss H et al (1984) Comparison of tumor response in nude mice and in the patients. Behring Inst Mitt:343–352

    Google Scholar 

  7. Hidalgo M, Bruckheimer E, Rajeshkumar NV et al (2011) A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 10:1311–1316. doi:10.1158/1535-7163.MCT-11-0233

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Fichtner I, Slisow W, Gill J et al (2004) Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40:298–307. doi:10.1016/j.ejca.2003.10.011

    Article  CAS  PubMed  Google Scholar 

  9. Merk J, Rolff J, Becker M et al (2009) Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg 36:454–459. doi:10.1016/j.ejcts.2009.03.054

    Article  PubMed  Google Scholar 

  10. Whittle JR, Lewis MT, Lindeman GJ, Visvader JE (2015) Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res 17:17. doi:10.1186/s13058-015-0523-1

    Article  PubMed  PubMed Central  Google Scholar 

  11. Mattie M, Christensen A, Chang MS et al (2013) Molecular characterization of patient-derived human pancreatic tumor Xenograft models for preclinical and translational development of cancer therapeutics 1,2. Neoplasia 15:1138–1150. doi:10.1593/neo.13922

    Article  PubMed  PubMed Central  Google Scholar 

  12. Park B, Jeong BC, Choi Y-LL et al (2013) Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue. Cancer Sci 104:1–8. doi:10.1111/cas.12123

    Article  Google Scholar 

  13. Bernardo C, Costa C, Amaro T et al (2014) Patient-derived sialyl-Tn-positive invasive bladder cancer xenografts in nude mice: an exploratory model study. Anticancer Res 34:735–744

    CAS  PubMed  Google Scholar 

  14. McCue PA, Gomella LG, Veltri RW et al (1996) Development of secondary structure, growth characteristics and cytogenetic analysis of human transitional cell carcinoma xenografts in scid/scid mice. J Urol 155:1128–1132

    Article  CAS  PubMed  Google Scholar 

  15. Abe T, Tada M, Shinohara N et al (2006) Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice. Int J Urol 13:47–57. doi:10.1111/j.1442-2042.2006.01220.x

    Article  PubMed  Google Scholar 

  16. Pan C, Zhang H, Tepper CG et al (2015) Development and characterization of bladder cancer patient-derived Xenografts for molecularly guided targeted therapy. PLoS One 10:e0134346. doi:10.1371/journal.pone.0134346

    Article  PubMed  PubMed Central  Google Scholar 

  17. Jäger W, Xue H, Hayashi T et al (2015) Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget 6:21522–21532. doi:10.18632/oncotarget.3974

    Article  PubMed  PubMed Central  Google Scholar 

  18. Bernardo C, Costa C, Sousa N et al (2015) Patient-derived bladder cancer xenografts: a systematic review. Transl Res 166:324–331. doi:10.1016/j.trsl.2015.02.001

    Article  PubMed  Google Scholar 

  19. Workman P, Aboagye EO, Balkwill F et al (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102:1555–1577. doi:10.1038/sj.bjc.6605642

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Rubio-Viqueira B, Jimeno A, Cusatis G et al (2006) An platform for translational drug development in pancreatic cancer. Clin Cancer Res 12:4652–4661. doi:10.1158/1078-0432.CCR-06-0113

    Article  CAS  PubMed  Google Scholar 

  21. Choi YY, Lee JE, Kim H et al (2016) Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci Rep 6:22172. doi:10.1038/srep22172

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Calles A, Rubio-Viqueira B, Hidalgo M (2013) Primary human non-small cell lung unit and pancreatic tumorgraft models-utility and applications in drug discovery and tumor biology. Curr Protoc Pharmacol:1–21. doi:10.1002/0471141755.ph1426s61

Download references

Author information

Authors and Affiliations

  1. Experimental Pathology and Therapeutics Group—Research Center, Portuguese Oncology Institute—Porto (IPO-Porto), Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal

    Carina Bernardo & Lúcio Lara Santos

  2. Institute for Biomedicine (IBiMED), University of Aveiro, Porto, Portugal

    Carina Bernardo

  3. Department of Surgical Oncology, Portuguese Oncology Institute—Porto (IPO-Porto), Porto, Portugal

    Lúcio Lara Santos

Authors
  1. Carina Bernardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lúcio Lara Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carina Bernardo .

Editor information

Editors and Affiliations

  1. Department of Urology, Heinrich Heine University, Düsseldorf, Germany

    Wolfgang A Schulz

  2. Department of Urology, Heinrich Heine University, Düsseldorf, Germany

    Michèle J. Hoffmann

  3. Department of Urology, Heinrich Heine University, Düsseldorf, Germany

    Günter Niegisch

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Bernardo, C., Santos, L.L. (2018). Patient-Derived Bladder Cancer Xenografts. In: Schulz, W., Hoffmann, M., Niegisch, G. (eds) Urothelial Carcinoma. Methods in Molecular Biology, vol 1655. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7234-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7234-0_14

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7233-3

  • Online ISBN: 978-1-4939-7234-0

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation